Therapeutic inhibitor of vascular smooth muscle cells
AssigneeNeoRx Corporation
InventorsLawrence L. Kunz, Richard A. Klein
Life of this patent
Estimating the term…
Abstract
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
Claims72
A method for maintaining vessel luminal area following vascular trauma, which method comprises:
- administering to a mammal a sustained release dosage form comprising a cytostatic amount of a therapeutic agent which inhibits vascular smooth muscle cell contraction or migration and which does not exhibit substantial cytotoxicity.
A method for maintaining vessel luminal area following vascular trauma, which method comprises:
- administering to the vessel a cytostatic amount of a therapeutic agent which inhibits vascular smooth muscle cell contraction or migration and which does not exhibit substantial cytotoxicity, wherein the therapeutic agent is administered directly or indirectly to a traumatized vessel, and wherein the therapeutic agent is a cytoskeletal inhibitor or an analog thereof.
A method for maintaining vessel luminal area following vascular trauma, which method comprises administering to a mammal the following:
- (a) a therapeutic formulation comprising a cytocidal agent and a binding protein or peptide capable of specifically binding to vascular smooth muscle cells, stromal cells or interstitial matrix surrounding vascular smooth muscle cells;
- and
- (b) a sustained release dosage form comprising an effective amount of a cytostatic therapeutic agent which does not exhibit substantial cytotoxicity.
A method for inhibiting vascular smooth muscle cells of a mammal, which method comprises administering to the mammal a dosage form comprising a polymeric matrix comprising an amount of a cytoskeletal inhibitor effective to inhibit vascular smooth muscle cell contraction or migration without substantial cytotoxicity to the cells, wherein the dosage form is bound to a binding peptide or protein capable of specifically binding to vascular smooth muscle cells, stromal cells, or interstitial matrix surrounding vascular smooth muscle cells.
A method for inhibiting vascular smooth muscle cells of a mammal for a sustained period of time to achieve a therapeutic objective, which method comprises administering to the mammal a sustained release dosage form comprising an amount of a cytoskeletal inhibitor effective to inhibit vascular smooth muscle cell contraction or migration without substantial cytotoxicity to the cells.
A method for treating a traumatized vessel, which method comprises:
- administering to a mammal a sustained release dosage form comprising an amount of a cytoskeletal inhibitor effective to inhibit the contraction or migration of smooth muscle cells.
A method for biological arteromyectomy, which method comprises administering to a mammal the following:
- a cytocidal conjugate comprising a cytocidal agent and a binding partner capable of specifically binding to vascular smooth muscle cells, stromal cells or interstitial matrix surrounding vascular smooth muscle cells;
- and a sustained release dosage form comprising an amount of a cytoskeletal inhibitor effective to inhibit the contraction or migration of smooth muscle cells.
A method for maintaining vessel luminal area following vascular trauma, which method comprises:
- administering to a mammal a sustained release dosage form comprising an effective amount of a cytostatic therapeutic agent which inhibits vascular smooth muscle cell contraction or migration and which does not exhibit substantial cytotoxicity, wherein the sustained release dosage form comprises an attached binding peptide or protein capable of specifically binding to vascular smooth muscle cells, stromal cells or interstitial matrix surrounding vascular smooth muscle cells.
Dependencies are inferred from the claim text.